Study 200170: A Rollover Study to Provide Continued Treatment with Eltrombopag

Phase 4

Completed

• Conditions: thrombocytopenia; decrease number of platelets; 10018849

• Registration Number: NL-OMON44543
• Lead Sponsor: GlaxoSmithKline

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 2

Inclusion Criteria

* The subject is participating in a GSK sponsored investigational study of eltrombopag (parent study) within the past 28 days and is receiving clinical benefit without unacceptable toxicity as determined by the investigator.
* Female participants and female partners of male participants of child-bearing potential: subject must not be sexually active or is practicing an acceptable method of contraception.

Exclusion Criteria

* Permanent discontinuation of eltrombopag in the parent study based upon the study treatment discontinuation or study withdrawal criteria from the parent study.
Subjects who permanently discontinued treatment because they completed all study related treatments remain eligible.
* Pregnancy and breast feeding. Inadequate contraception, if relevant.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Adverse effects.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>None.</p><br>